In recent news, the generic drugmaker Stada has reportedly separated its Russian business, establishing a distinct entity named Nizhpharm, as per information from the Welt am Sonntag newspaper. A spokesperson from Stada confirmed this development, stating that Nizhpharm will now function independently and autonomously.
As of now, Stada has chosen not to comment on the specifics of the report. However, it’s worth noting that the private equity owners of Stada, recognized for selling a range of consumer healthcare products including painkillers and sunscreen lotions, along with biosimilar and generic drugs, are said to be contemplating strategic options. These options include the potential sale of the company or an initial public offering (IPO), according to sources familiar with the matter.
The situation suggests a strategic move by Stada to reorganize its operations, particularly in the Russian market, and explore different avenues for the future, including the possibility of a sale or IPO.
Related posts:
International Flavors & Fragrances (IFF) Explores Potential $3.5 Billion Sale of Pharma Solutions Business
Ondansetron STADA 4mg: Uses, Benefits, Dosage, Side Effects
Teva Secures Early Launch of Generic Vivitrol After Settling Patent Case with Alkermes
Cabometyx Patent Battle Resolved As Exelixis Grants Teva 2031 Generic License in Settlement
